Ann: Half Year Accounts - Appendix 4D, page-2

The only part of the update I am interested in at this stage:

A new customer engagement in a Continuous Glucose Monitoring solution has produced a sensor expected to ramp materially late in FY21. The SARS-CoV-2 sensor developed in conjunction with NanoDx has progressed through the R&D phase and the final product is now in the hands of NanoDx. The Group has engaged in a material agreement that will be fully disclosed once the sensor reaches FDA approval. The Group was also able to engage and develop a laser-based sensor that hit key milestones late in the first half of FY21 to ensure a production level product could be attained and potentially ramp in FY22.